Challenging case of tinea corporis and faciei in psoriatic patient treated with bimekizumab: The usefulness of mycological screening before biological therapies

Challenging case of tinea corporis and faciei in psoriatic patient treated with bimekizumab: The usefulness of mycological screening before biological therapies

Psoriasis is a multifactorial immune-mediated disorder linked to the interleukin (IL)-17 signalling pathway. We present an unusual case of tinea corporis and faciei caused by Trichophyton tonsurans that developed after starting the IL-17A/F inhibitor bimekizumab. Our case underlines how psoriatic pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Terenzio Cosio, Ruslana Gaeta Shumak, Cristiana Borselli, Fabio Artosi, Roberta Gaziano, Elena Campione
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Medical Mycology Case Reports
Subjects:
Bimekizumab
Psoriasis
Interleukin-17
Tinea corporis
Tinea faciei
Online Access:http://www.sciencedirect.com/science/article/pii/S2211753924000575
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Psoriasis is a multifactorial immune-mediated disorder linked to the interleukin (IL)-17 signalling pathway. We present an unusual case of tinea corporis and faciei caused by Trichophyton tonsurans that developed after starting the IL-17A/F inhibitor bimekizumab. Our case underlines how psoriatic patients, treated with IL-17 inhibitors, should be screened for cutaneous fungal infections before and during treatment, in order to exclude a concomitant infection or the risk of its exacerbation.
ISSN:2211-7539

Similar Items